Roch Houot, MD, PhD - CHU Rennes - Professor

Roch Houot

MD, PhD

CHU Rennes

Professor

Rennes, Bretagne | France

Main Specialties: Hematology & Oncology

ORCID logohttps://orcid.org/0000-0003-1729-8213

Roch Houot, MD, PhD - CHU Rennes - Professor

Roch Houot

MD, PhD

Introduction

Primary Affiliation: CHU Rennes - Rennes, Bretagne , France

Specialties:

Publications

70Publications

2282Reads

30Profile Views

Renal Dysfunction in Patients With Direct Infiltration by B-Cell Lymphoma.

Kidney Int Rep 2019 May 12;4(5):688-697. Epub 2019 Feb 12.

CHU de Rennes, Service de Néphrologie, Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ekir.2019.02.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506703PMC
May 2019
16 Reads

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.

Leukemia 2018 11 12;32(11):2307-2315. Epub 2018 Oct 12.

CHU Rennes, Service Hématologie Clinique, 35033, Rennes, France.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0285-8
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0285-8DOI Listing
November 2018
17 Reads
10.431 Impact Factor

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Haematologica 2018 08 13;103(8):1256-1268. Epub 2018 Jul 13.

CHU Rennes, Service Hématologie Clinique, F-35033, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.184192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068015PMC
August 2018
9 Reads
5.868 Impact Factor

Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Blood 2018 07 2;132(1):9-16. Epub 2018 May 2.

Division of Hematology, University of Colorado, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-02-811174DOI Listing
July 2018
4 Reads
10.452 Impact Factor

Checkpoint blockade after kidney transplantation.

Eur J Cancer 2018 06 26;96:111-114. Epub 2018 Apr 26.

CHU Pontchaillou, Department of Hematology, Rennes, France; INSERM, U1236, Rennes, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.03.019DOI Listing
June 2018
7 Reads
5.417 Impact Factor

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

Eur J Cancer 2018 03;91:136-144

Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Gustave Roussy, Université Paris-Saclay, Département D'hématologie, Villejuif F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.015DOI Listing
March 2018
56 Reads
5.417 Impact Factor

Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis.

JAMA Dermatol 2018 01;154(1):113

Department of Hematology, CHU Rennes, Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2017.4421DOI Listing
January 2018
11 Reads

NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.

Oncoimmunology 2018 20;7(4):e1409322. Epub 2017 Dec 20.

INSERM U1183, Université de Montpellier 1, UFR Médecine, Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1409322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889292PMC
December 2017
11 Reads
6.283 Impact Factor

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

N Engl J Med 2017 09;377(13):1250-1260

From Service d'Hématologie Clinique (S.L.G., T.G.), Service d'Anatomopathologie (A.M.), and Service d'Hématologie Biologique (M.C.B.), Hôtel-Dieu Centre Hospitalier Universitaire (CHU) de Nantes, and Centre de Recherche en Cancérologie et Immunologie (S.L.G., M.C.B.) and Faculté de Médecine (S.L.G.), Université de Nantes, Nantes, Hemato-Oncologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Université Diderot Sorbonne Paris-Cité (C.T.), Université Descartes (C.T.), Département d'Hématologie, Faculté de Médecine, Université Paris-Sud (V.R.), Département d'Anatomopathologie (D.C.) and Département d'Hématologie (O.H.), Necker Hospital, APHP, Sorbonne Paris-Cité, and INSERM Unité 1163 et Centre National de la Recherche Scientifique (CNRS) Équipe de Recherche Labellisée 8654, Imagine Institute (O.H.), Paris, Département d'Hématologie, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse (L.O.), Service d'Hématologie Clinique et Thérapie Cellulaire, CHU de Bordeaux, Bordeaux (K.B.), Service d'Hématologie et Thérapie Cellulaire, CHU de Tours, Tours (C.D.), Service d'Hématologie, CHU d'Amiens, Amiens (G.D.), INSERM, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif (V.R.), Département d'Hématologie, CHU de Nancy, Nancy (P.F.), INSERM Unité 954, Vandoeuvre (P.F.), Service d'Hématologie Clinique, CHU de Dijon, and INSERM Unité Mixte de Recherche 1231, Dijon (O.C.), Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon (H.Z.), Lymphoid Malignancies Unit, Hôpital Henri Mondor, APHP, Créteil (C.H.), Service d'Hématologie du Centre Hospitalier de Vendée, La Roche-sur-Yon (H.M.), Service Hématologie Clinique (R.H.) and Département d'Hématologie (T.L.), CHU de Rennes, INSERM Unité 917 (R.H.), and INSERM Unité 1236 (T.L.), Rennes, Département d'Hematology, Centre Henri-Becquerel et Université de Normandie Unité 1245, Rouen (F.J., H.T.), Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, CHU de Clermont-Ferrand et Université Clermont Auvergne, Clermont-Ferrand (O.T.), Service d'Hématologie, Clinique Victor Hugo, Le Mans (K.L.D.), Department of Hematology, Université de Lille, Groupe de Recherche sur les Formes Injectables et les Technologies Associées, and CHU de Lille, Lille (F.M.), Département d'Hématologie Clinique, CHU de Montpellier, CNRS UMR 5235, Montpellier (G.C.), Service d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg (L.-M.F.), INSERM 1209, CNRS UMR 5309, Faculté de Médecine, Université Grenoble Alpes (M.C., R.G.), Institute for Advanced Biosciences (M.C.), and Laboratoire de Génétique Onco-hématologie (M.C.) and Faculté de Médecine (R.G.), CHU de Grenoble Alpes, Grenoble, Service d'Hématologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite (G.S.), and Université Claude Bernard Lyon 1 and Cancer Research Center of Lyon, INSERM 1052 CNRS 5286 Lyon, Lyon (G.S.) - all in France; and Département d'Hématologie, Cliniques Universitaires Saint-Luc-Université Catholique de Louvain, Brussels (E.V.D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1701769DOI Listing
September 2017
81 Reads
55.873 Impact Factor

"Chronic myelogenous leukemia in primary blast crisis" rather than "de novo -positive acute myeloid leukemia".

Clin Case Rep 2017 06 4;5(6):757-760. Epub 2017 Apr 4.

Department of Clinical Hematology University Hospital Rennes France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ccr3.937
Publisher Site
http://dx.doi.org/10.1002/ccr3.937DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458010PMC
June 2017
36 Reads

Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing.

Leuk Lymphoma 2017 04 23;58(4):1008-1012. Epub 2016 Sep 23.

a Laboratoire d'Hématologie, Pole de Biologie, Centre Hospitalier Universitaire de Rennes , Rennes , France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1225208DOI Listing
April 2017
8 Reads

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Eur J Cancer 2016 11 15;68:134-147. Epub 2016 Oct 15.

CHU Rennes, Service Hématologie Clinique, F-35033, Rennes, France; INSERM, U917, F-35043, Rennes, France. Electronic address:

View Article

Download full-text PDF

Source
http://www.ejcancer.com/article/S0959804916324315/pdf
Web Search
https://www.researchgate.net/publication/309184910_Turning_t
Web Search
https://linkinghub.elsevier.com/retrieve/pii/S09598049163243
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2016.09.010DOI Listing
November 2016
27 Reads
5.417 Impact Factor

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Neuro Oncol 2016 09 6;18(9):1297-303. Epub 2016 Mar 6.

Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive

View Article

Download full-text PDF

Source
https://academic.oup.com/neuro-oncology/article-lookup/doi/1
Publisher Site
http://dx.doi.org/10.1093/neuonc/now033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998995PMC
September 2016
170 Reads
5.562 Impact Factor

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.

Blood 2016 08 23;128(8):1081-92. Epub 2016 Jun 23.

Pôle Biologie and INSERM, Unité Mixte de Recherche U917, Equipe Labellisée Ligue Contre le Cancer, Rennes, France; Université Rennes 1, Unité Mixte de Recherche U917, Rennes, France; Etablissement Français du Sang Bretagne, Rennes, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-662783DOI Listing
August 2016
22 Reads
10.452 Impact Factor

Holbrook Kohrt: In Memoriam (1977-2016).

Clin Cancer Res 2016 07;22(14):3695-6

Drug Development Department, INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1181DOI Listing
July 2016
42 Reads
8.722 Impact Factor

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.

Clin Cancer Res 2016 Feb 18;22(4):787-9. Epub 2015 Dec 18.

Department of Medicine, Division of Oncology, Stanford University, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2777DOI Listing
February 2016
14 Reads
8.722 Impact Factor

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Cancer Immunol Res 2015 Oct;3(10):1115-22

Department of Medicine, Division of Oncology, Stanford University, Stanford, California.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/cgi/doi/10.1158/232
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-15-0190DOI Listing
October 2015
27 Reads

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.

Curr Opin Immunol 2015 Apr 7;33:1-8. Epub 2015 Jan 7.

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2014.12.010DOI Listing
April 2015
25 Reads
7.478 Impact Factor

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies.

Oncoimmunology 2014;3(7):e941740. Epub 2014 Jul 3.

Department of Medicine, Division of Oncology; Stanford University ; Stanford, CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21624011.2014.941740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292240PMC
July 2014
20 Reads
6.283 Impact Factor

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Clin Cancer Res 2014 Jan 16;20(1):213-20. Epub 2013 Oct 16.

Authors' Affiliations: Institut Gustave Roussy, Villejuif; Centre Hospitalier Universitaire Henri Mondor-Chenevier, Creteil; Centre Henri Becquerel, Rouen; Centre Hospitalier Universitaire de Lille, Lille; Centre Hospitalier Universitaire Pontchaillou, Rennes; Sanofi, Paris; Hospices Civils de Lyon and Université Lyon-1, Lyon, France; and ImmunoGen, Inc., Waltham, Massachusetts.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/20/1/213.full.
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-0580DOI Listing
January 2014
27 Reads
8.722 Impact Factor

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody.

Oncoimmunology 2012 Sep;1(6):957-958

CHU Rennes; Serivice Hématologie Clinique; Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.19974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489758PMC
September 2012
16 Reads
6.283 Impact Factor

Combination strategies to enhance antitumor ADCC.

Immunotherapy 2012 May;4(5):511-27

Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/imt.12.38
Publisher Site
http://dx.doi.org/10.2217/imt.12.38DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386352PMC
May 2012
47 Reads
2.440 Impact Factor

[Malignant lymphoma].

Rev Prat 2012 Apr;62(4):547-54

Service d'hématologie clinique, CHU de Rennes, 35033 Rennes, France.

View Article

Download full-text PDF

Source
April 2012
4 Reads

Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.

Cancer Res 2012 Mar 9;72(5):1239-47. Epub 2012 Jan 9.

Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-3375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3294169PMC
March 2012
5 Reads
9.329 Impact Factor

Cutaneous macroglobulinosis treated with bortezomib and rituximab.

Eur J Haematol 2011 Jul 25;87(1):98. Epub 2011 May 25.

Department of Hematology, CHU Rennes, Hôpital Pontchaillou, Rennes, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1600-0609.2011.01610.x
Publisher Site
http://dx.doi.org/10.1111/j.1600-0609.2011.01610.xDOI Listing
July 2011
15 Reads
2.066 Impact Factor

Immunomodulating antibodies and drugs for the treatment of hematological malignancies.

Cancer Metastasis Rev 2011 Mar;30(1):97-109

Service d'Hématologie Clinique & INSERM U917, Centre Hospitalier Universitaire de Rennes, Rennes, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10555-011-9274
Web Search
http://link.springer.com/10.1007/s10555-011-9274-3
Publisher Site
http://dx.doi.org/10.1007/s10555-011-9274-3DOI Listing
March 2011
3 Reads
7.234 Impact Factor

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

Blood 2011 Feb 30;117(8):2423-32. Epub 2010 Dec 30.

Department of Medicine, Division of Oncology, Stanford University Medical Center, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2010-08-301945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062409PMC
February 2011
56 Reads
10.452 Impact Factor

Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.

Eur J Nucl Med Mol Imaging 2010 Dec 18;37(12):2307-14. Epub 2010 Aug 18.

Nuclear Medicine Department, Eugène Marquis Anticancer Centre, Rennes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-010-1539-5DOI Listing
December 2010
23 Reads
5.383 Impact Factor

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.

Proc Natl Acad Sci U S A 2010 Jul 11;107(29):12747-54. Epub 2010 Jun 11.

Department of Medicine, Oncology Division, Stanford University, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.1002057107
Publisher Site
http://dx.doi.org/10.1073/pnas.1002057107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919949PMC
July 2010
21 Reads
9.809 Impact Factor

Vaccines for lymphomas: idiotype vaccines and beyond.

Blood Rev 2009 May 31;23(3):137-42. Epub 2008 Oct 31.

Department of Medicine, Oncology Division, Stanford University, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2008.09.001DOI Listing
May 2009
1 Read
5.565 Impact Factor

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.

Blood 2009 Apr 21;113(15):3546-52. Epub 2008 Oct 21.

Department of Medicine, Division of Oncology, Stanford University, CA 94305-5151, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2008-07-17
Publisher Site
http://dx.doi.org/10.1182/blood-2008-07-170274DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668854PMC
April 2009
8 Reads
10.452 Impact Factor

Idiotype vaccination for lymphoma: moving towards optimisation.

Leuk Lymphoma 2009 Jan;50(1):1-2

Oncology Division, Department of Medicine, Stanford University, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802517807DOI Listing
January 2009
2 Reads

Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis.

Dermatology 2006 ;213(3):239-41

Service de Dermatologie, Hôpital de l'Hôtel-Dieu, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000095044DOI Listing
January 2007
4 Reads
1.685 Impact Factor

Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation.

J Immunol 2006 May;176(9):5293-8

Department of Hematology, Centre Hospitalier Lyon Sud, 69310 Pierre-Benité, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.176.9.5293DOI Listing
May 2006
49 Reads
4.922 Impact Factor

Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma.

Eur Cytokine Netw 2006 Mar;17(1):60-6

Equipe d'Accueil Pathologie des Cellules Lymphoïdes, Université Claude Bernard, Lyon, France.

View Article

Download full-text PDF

Source
March 2006
3 Reads
1.960 Impact Factor

Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome.

Hematology 2004 Oct-Dec;9(5-6):369-76

Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245330400001983DOI Listing
April 2005
6 Reads
1.189 Impact Factor

Top co-authors

Ronald Levy
Ronald Levy

Stanford University

19
Thierry Lamy
Thierry Lamy

Université Rennes 1

14
Franck Morschhauser
Franck Morschhauser

Centre Hospitalier Universitaire

14
Holbrook E Kohrt
Holbrook E Kohrt

Stanford University

14
Krimo Bouabdallah
Krimo Bouabdallah

University Hospital

11
Guillaume Cartron
Guillaume Cartron

Université Montpellier I

11
Matthew J Goldstein
Matthew J Goldstein

Stanford University

10
Aurelien Marabelle
Aurelien Marabelle

Institute de Gustave Roussy Service

9
Ash A Alizadeh
Ash A Alizadeh

Stanford University

7